Summary This open-label, non-randomized, parallel-group trial investigated the pharmacokinetics of raltitrexed (Tomudex, formerly ZD1 694) after a single intravenous dose of 3.0 mg m-2, comparing eight cancer patients with mild to moderate renal impairment (creatinine clearance 25-65 ml min-') with eight cancer patients with normal renal function (creatinine clearance >65 ml min-'). The primary end points were area under the plasma raltitrexed concentration-vime curve from the start of the infusion to the last determined concentration (AUCo_) and AUC to infinity (AUCo); secondary end points were peak corncentrations of ralftitrexed (C,n,,) and elimination half-life (t,>). The groups were compared statistically using analysis of covariance. The AUCs were greater for patients with renal impairment than for patients with normal renal function (2452.2 compared with 1247.3 ng h ml-' for AUCo._. (ratio 1.97; 95% Cl 1.36-2.84); 2961.5 compared with 1457.0 ng h ml-' for AUCo_ (ratio 2.03; 1.25-3.29). These differences were statistically significant (P = 0.002 and P = 0.008 for AUC,, and AUCo_ respectively. 50-lOO h (Clarke et al. 1996). This prolonged t1,, may represent hydrolysis of the polvalutamated
Raltitrexed (Tomudex. ZD1694: Zeneca Limited) is a cytotoxic agent w-hich acts by direct and specific inhibition of thymidydlate synthase. the enzyme catalysing a critical step in de novo DNA synthesis. i.e. the production of thymidine monophosphate from deoxvuridine monophosphate. Some clinically effective anticancer agents. such as 5-fluorouracil and methotrexate. act in part by inhibiting thymidylate synthase but also have effects on other enzyme pathways. xvhich may contribute to their anti-tumour activity and obserned toxicity profiles.
Raltitrexed inhibits thymidylate synthase selectively in vitro (Jackman et al. 1991) . Preclinical studies showed that raltitrexed enters cells rapidly usinc the reduced folate carrier. Once inside cells. it is conx erted efficiently bv folhpolyglutamate svnthetase to polyglutamated forms. which are markedlv more potent inhibitors of thvymidylate synthase than the parent compound. The polyglutamates are retained in cells and cause prolonged inhibition of th midv late synthase. which leads to DNA fragmentation and cell death. In humans. plasma concentrations of raltitrexed showed a triphasic decline after administration by a single 15-min intravenous infusion. The mean apparent half-life of the terminal (gamma) phase (tl, ,) was 50-lOO h (Clarke et al. 1996) . This prolonged t1,, may represent hydrolysis of the polvalutamated Sutton. Surrey SM2 5NG. UK forms and release of raltitrexed from tissues into the circulation. and allow s the druc to be administered as a single dose once ever 3 weeks.
In the phase I trial. a dose and schedule of 3.0mg m-' every 3 weeks was identified as suitable for phase H inxvestigation. Higher doses w-ere associated with significant asthenia. and antiproliferatixe toxicities. if thev occurred. showed a tendencv to be cumulative. In phase H trials. intravenous raltitrexed at a dose of 3.0 mg m-' once everv 3 weeks produced objectixe responses in several solid tumours including colorectal (Zalcberg et al. 1996) . breast (Smith et al. 1996) . ovarian (Gore et al. 1995) . pancreatic (Pazdur et al. 1996) and non-small-cell lung cancer (Heaxen et al. 1994) . In these trials. the safet) profile of raltitrexed was consistent with that expected for an active cvtotoxic agent of this class. As predicted. the most frequentlI observed toxicities were asthenia. diarrhoea. nausea and vomiting. leucopenia and reversible increases in aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT). The most serious (life-threatenin) toxicities were gyastrointestinal toxicitx and haematological suppression.
This open-label. non-randomized. parallel-group trial w-as undertaken to determine the effect of mild to moderate renal impairment on the pharmacokinetics of raltitrexed after administration of a sinale intravenous dose of 3.0 mgr m-.
PATIENTS AND METHODS Patients
The study was 
Trial _etment
Each patient received a single intravenous dose of 3.0 mg m-2 raltitrexed administered as a 15-min infusion, and was then monitored for 28 days. Patients showing clinical benefit after this first dose of raltitrexed could continue treatment at intervals of 3 weeks. In the event of toxicity, treatment could be delayed by up to 3 weeks or the dose of raltitrexed could be reduced.
Assessments
The patients remained in hospital for 48 h after the first dose of raltitrexed and then returned at 1, 2, 3 and 4 weeks after dosing.
Patients who then continued raltitrexed treatment were seen routinely at 3-week intervals for dosing and again 3 weeks after the last dose.
Pharmacok*netcs
Raltitrexed pharmacokinetics were assessed after the first dose only. Blood samples were collected before the first dose and at 5. 10 and 15 min (during the infusion) then and at 20, 25, 30. 45, 60 and 90 min. 2, 3, 5, 8, 12 and 24 h, and days 3, 8, 15, 22 and 29 after the first dose. Concentrations of raltitrexed in plasma were measured using a radioimmunoassay by Zeneca Pharmaceuticals, UK (Clarke et al, 1996) . The limit of quantification of the assay was 0.768 ng ml-.
The peak plasma concentration (C ) and the time to Cn ( tr,) were calculated directly from raltitrexed concentration data The area under the plasma concentration-time curve from the start of the infusion to the time of the last determined concentration (AUCO.,.) was calculated using the linear trapezoidal rule, by the pharmacokinetic analysis program PHASAR (version 1.2). The following pharmacokinetic parameters were calculated by fitting a non-linear regression model to the data using the MODFIT data analysis program (version 5): the AUC to infinity (AUCQ; the volume of the central compartment (V) and volume at steady state (V5s); (tl) and the terminal phase half-life (tIrr); and the clearance, which was calculated by dividing the actual dose in mg by the AUC,,. A three-compartment model with infusion input was used with a weighting factor of I/concentration2 for 12 patients.
For four patients (two in each group), a weighting factor of 1/concentration (Clarke et al, 1996) was used to improve the fit of the terminal phase as determined by the Akaike information criteria of the data. The model also generated the microrate constants for the transfer of raltitrexed between the three compart- 
Sa l iiehods
The primary end points were AUCo: and AUCQkk and the secondary end points were C. and t,. These paraneters were compared between groups of patients using analysis of covariance. Because there was an imbalance in the numbers of men and women in the two renal function groups (see Table 1 ), each end point was analysed in two stages. The first stage examined the effects of renal function and the second the effects of gender. Both analyses were adjusted for age and weight at entry. AUC(-, AUCo s& and C , were log transformed before analysis. The analysis results were back-transformed and presented as adjusted geometric least squares means (glsmeans), and ratios (impaired-normal renal function.
female-male) with 95% confidence limits and associated P-values.
The t,r was not log transformed, and the analysis results were Table 2 . Peak concentrations of raltitrexed were found in the samples taken either immediately before or immediately after the end of the infusion for all patients except one, for whom tMa occurred at 6 mmn before the end of the infusion. In both groups of patients. plasma concentrations of raltitrexed declined triexponentially after the peak and could be described using a threecompartment pharmacokinetic model (Figures 1 and 2 ). The t was between 30 mmi and 12 h after the end of the infusion and the terminal phase was from 24 h onwards (Figure 2 ). The terminal phase accounted for approximately two-thirds of the AUC for the patients with normal renal function and approximately threequarters of the AUC for the patients with renal impairment.
Mean AUC,,and AUCc, were approximately double for the patients with renal impairment compared with those with normal renal function (Table 3 ). The analysis of covariance showed a statistically significant difference between the groups for both AUCo (P = 0.002) and AUC, (P = 0.008). The difference in CmL values between the groups was not statistically significant (P = 0.204). but tl , was statistically significantly longer in the group with renal impairment (P = 0.030).
The relationship between raltitrexed clearance and calculated creatinine clearance is depicted in Figure 3 [creatinine clearance was calculated using Cockcroft's equation (Cockcroft and Gault. 1976 Raltitrexed pharmacokinetcs and renal function 1191 The safety profile of raltitrexed in this trial was consistent with that seen in phase II trials. The most frequent adverse events and laboratory abnormalities were myelosuppression. nausea and vomiting. infection. and asthenia. With one marked exception. raltitrexed was well tolerated by both patient groups. although. as may be predicted. the patients with normal renal function appeared to tolerate therapy better than patients with compromised renal function. Overall. there was no clear relationship between pharmacokinetic parameters and the incidence of severe toxicity. For the antimetabohite class of cytotoxics. this lack of relationship is not surprising because toxicity is often not predictable from pharmacokinetic data (EORTC PAMM Group. 1987).
In conclusion. there was a clear effect of renal impairment on the pharmacokinetics of raltitrexed: for patients with mild to moderate renal impairment. raltitrexed clearance w-as delayed. and elimination half-life and AUC increased compared with the group with normal renal function. In addition. there was some evidence that raltitrexed at a dosage of 3.0 mg m-every 3 weeks was less well tolerated by the patients with impaired renal function. These results suggest that a reduction in raltitrexed dose and an increased interval between doses is recommended for patients with mild to moderate renal impairment. The dose of raltitrexed should be reduced by 50% in patients with a creatinine clearance between 25 and 65 ml mmn-' and the dosage interval be increased to 4 w-eeks.
In patients with a creatinine clearance below 25 ml min-'. the use of raltitrexed is not advised.
